What is it about?

The C3G Trial Endpoints Work Group assesed the evidence and uncertainties of the three prespecified endpoints as measures of clinical benefit in two ongoing clinical trials for C3G and opined on the efficacy findings that would warrant approval of the test agents as treatment for C3G.

Featured Image

Read the Original

This page is a summary of: DEVELOPING THERAPIES FOR C3G: REPORT OF THE KIDNEY HEALTH INITIATIVE C3G TRIAL ENDPOINTS WORK GROUP, Clinical Journal of the American Society of Nephrology, June 2024, Wolters Kluwer Health,
DOI: 10.2215/cjn.0000000000000505.
You can read the full text:

Read

Contributors

The following have contributed to this page